Scholarlink

Purpose <p>Sepsis requires stratification for host-directed therapies through the discovery of adequate biomarkers enabling prediction of outcomes and treatment responses. Adrenomedullin has previously demonstrated potential for prognostic enrichment. This study aimed to assess associations of bioactive adrenomedullin (bio-ADM) levels at ICU admission and sepsis outcomes and to evaluate the potential of bio-ADM as marker to identify subgroups of patients with moderate disease severity that might benefit from hydrocortisone treatment.</p> Methods <p>We used data from the HYPRESS trial (NCT00670254) to investigate, if bio-ADM is useful to predict sepsis outcomes (septic shock, 90- and 180-day mortality) and benefit or harm by hydrocortisone treatment. Optimal cut-offs for outcome predictions were determined by Youden’s index. Logistic regression was used to assess bio-ADM subgroups and treatment interaction.</p> Results <p>Bio-ADM levels differed significantly in patients with or without septic shock within 14 days (p = 0.011). While the area under the ROC curve (AUC) was only 0.603 (CI 0.531–0.676), patient subgrouping using bio-ADM levels showed significantly higher cumulative incidence of septic shock within 14 days in the subgroup of patients with bio-ADM levels ≥ 37 pg/mL (p &lt; 0.001). The odds ratio for the development of septic shock in this group was 4.67 (95% CI 1.53, 20.3, p = 0.016). A bio-ADM cut-off of ≥ 136 pg/mL was predictive for 90-day (OR 8.21, 95% CI 2.46–27.9, p &lt; 0.001) and 180-day mortality (OR 4.87, 95% CI 1.49–16.0, p = 0.008). Hydrocortisone therapy did not reduce the incidence of septic shock (OR 1.59, 95% CI 0.37–8.15, p = 0.54), 90-day (OR 1.53, p = 0.23) or 180-day mortality (OR 1.41, p = 0.25), regardless of bio-ADM stratification (interaction term p = 0.58 for septic shock; p = 0.31 for 90-day mortality; p = 0.51 for 180-day mortality).</p> Conclusions <p>Whereas bio-ADM levels are associated with sepsis outcomes, our data do not indicate usefulness of the marker to identify patients potentially benefitting from hydrocortisone therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical value of circulating bioactive adrenomedullin for prediction of outcome and hydrocortisone response in sepsis patients—a post-hoc analysis of the HYPRESS trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月30日

查看全文
  • Caroline Neumann,
  • Margit Leitner,
  • Frank Bloos,
  • Dorothea Lange,
  • Holger Bogatsch,
  • Djillali Annane,
  • Jerôme Fleuriet,
  • Josef Briegel,
  • Michael Bauer,
  • Michael Bauer,
  • Thorsten Brenner,
  • Patrick Meybohm,
  • Josef Briegel,
  • Markus Weigand,
  • Matthias Gründling,
  • Holger Bogatsch,
  • Markus Loeffler,
  • Michael Kiehntopf,
  • Frank Bloos,
  • Gunnar Elke,
  • Sandra Frank,
  • Melanie Meersch-Dini,
  • Christian Putensen,
  • Achim Kaasch,
  • Stefan Kluge,
  • Sara Aly Abdelghany,
  • Maha Aly Khalaf Aly,
  • Mohamed Gamal Elansary,
  • Shereen Mustafa Elgengeehy,
  • Heba Mostafa Elwi,
  • Yasser Sadek Nassar,
  • Rania Yehia Hash,
  • Djillali Annane,
  • Rania Bouneb,
  • Zaineb Chelly-Dagdia,
  • Katy Diallo,
  • Jérome Fleuriet,
  • Henri-Jean Garchon,
  • Stanislas Grassin Delyle,
  • Rahma Hellali,
  • Nicholas Heming,
  • Nicolas Hunzinger,
  • Elodie Lamy,
  • Jihene Mahmoud,
  • Virginie Maxime,
  • Pierre Moine,
  • Camille Roquencourt,
  • Marie Alice Vovy,
  • Karine Zeitouni,
  • Manuela Adling-Ehrhardt,
  • Micheal Bauer,
  • Josef Briegel,
  • Bloos Frank,
  • Sandra Frank,
  • Katharina Habler,
  • Ludwig Hinske,
  • Rainer König,
  • Dorothea Lange,
  • Caroline Neumann,
  • Margit Leitner,
  • Marcus Oswald,
  • Christina Scharf-Janssen,
  • Michael Vogeser,
  • Carlos Flores,
  • Jesús Villar

摘要

Purpose

Sepsis requires stratification for host-directed therapies through the discovery of adequate biomarkers enabling prediction of outcomes and treatment responses. Adrenomedullin has previously demonstrated potential for prognostic enrichment. This study aimed to assess associations of bioactive adrenomedullin (bio-ADM) levels at ICU admission and sepsis outcomes and to evaluate the potential of bio-ADM as marker to identify subgroups of patients with moderate disease severity that might benefit from hydrocortisone treatment.

Methods

We used data from the HYPRESS trial (NCT00670254) to investigate, if bio-ADM is useful to predict sepsis outcomes (septic shock, 90- and 180-day mortality) and benefit or harm by hydrocortisone treatment. Optimal cut-offs for outcome predictions were determined by Youden’s index. Logistic regression was used to assess bio-ADM subgroups and treatment interaction.

Results

Bio-ADM levels differed significantly in patients with or without septic shock within 14 days (p = 0.011). While the area under the ROC curve (AUC) was only 0.603 (CI 0.531–0.676), patient subgrouping using bio-ADM levels showed significantly higher cumulative incidence of septic shock within 14 days in the subgroup of patients with bio-ADM levels ≥ 37 pg/mL (p < 0.001). The odds ratio for the development of septic shock in this group was 4.67 (95% CI 1.53, 20.3, p = 0.016). A bio-ADM cut-off of ≥ 136 pg/mL was predictive for 90-day (OR 8.21, 95% CI 2.46–27.9, p < 0.001) and 180-day mortality (OR 4.87, 95% CI 1.49–16.0, p = 0.008). Hydrocortisone therapy did not reduce the incidence of septic shock (OR 1.59, 95% CI 0.37–8.15, p = 0.54), 90-day (OR 1.53, p = 0.23) or 180-day mortality (OR 1.41, p = 0.25), regardless of bio-ADM stratification (interaction term p = 0.58 for septic shock; p = 0.31 for 90-day mortality; p = 0.51 for 180-day mortality).

Conclusions

Whereas bio-ADM levels are associated with sepsis outcomes, our data do not indicate usefulness of the marker to identify patients potentially benefitting from hydrocortisone therapy.